Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07325240 · ClinicalTrials.gov registry record · Phase 4
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
A Phase 4 study of Ocular Hypertension and Open Angle Glaucoma, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07325240 is a Phase 4 study of Ocular Hypertension and Open Angle Glaucoma that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 30 participants, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07325240, a Phase 4 study of Ocular Hypertension and Open Angle Glaucoma, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG) or ocular hypertension (OHT).
Conditions Studied
Interventions
- DRUG Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution
- DRUG Latanoprost 0.005% Ophthalmic Solution
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-11-21 |
| Est. Completion | 2027-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07325240
The ClinicalTrials.gov registry entry for NCT07325240 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 278-participant average among 54 other Ocular Hypertension trials with a reported enrollment target (89% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution is the first listed.
NCT07325240 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07325240 about?
NCT07325240 is a clinical study titled "24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients". The purpose of this study is to evaluate the effect on 24-hour IOP reduction of netarsudil-latanoprost fixed combination in one eye compared to latanoprost alone in the contralateral eye, dosed daily, 1 drop at night (QD, PM) in adult subjects, at least 18 years of age, with open angle glaucoma (OAG...
What is the current status of trial NCT07325240?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2025-11-21. Estimated completion is 2027-10.
What conditions does trial NCT07325240 study?
This clinical trial studies the following conditions: Ocular Hypertension, Open Angle Glaucoma.
What interventions are being tested in trial NCT07325240?
The interventions under investigation include: Netarsudil 0.01%/latanoprost 0.005% ophthalmic solution (DRUG), Latanoprost 0.005% Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT07325240?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07325240 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%
COMPLETED · Phase 4
-
Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 4
-
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
COMPLETED · Phase 4
-
DSLT for Reducing Medication in Glaucoma
RECRUITING
-
24-hour Wear Performance and Safety Study of Smartlens miLens Contact Lens for IOP Monitoring
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.